Myocor

Myocor® Inc. focuses on developing innovative therapeutic devices for heart disease, specifically through its Coapsys® System, aimed at optimizing patient care and outcomes related to geometrically remodeled hearts. Myocor® Inc. was founded in 1996 in Maple Grove, US, and specializes in developing devices for treating mitral insufficiency through the Coapsys® System.

The company was acquired by Edwards Lifesciences Corporation in October 2008, marking a significant pivot in its operational strategy. The founder's previous endeavors are not detailed. The company has raised a total of USD 24. 00 mn across its funding rounds, with the most recent being a Series D round led by Prism Venture Management, which closed on October 31, 2008.

Myocor® Inc. specializes in developing innovative therapeutic devices aimed at optimizing treatment options for patients with heart diseases related to geometrically remodeled hearts. Their core offering includes the Coapsys® System, a device specifically designed for the treatment of mitral insufficiency, which addresses the complex geometric changes that occur in the heart's structure. This technology, characterized by its proprietary Shape Change Therapy, aims to restore cardiac function by modifying the heart's geometry, thereby improving patient outcomes.

Myocor® serves a diverse client base, which includes healthcare providers, hospitals, and cardiologists primarily in North America and Europe, where there is a significant prevalence of heart disease requiring advanced treatment modalities. Myocor® Inc. generates revenue through direct sales of its flagship Coapsys® System to healthcare institutions and surgical centers specializing in cardiac care. The business model is primarily B2B, engaging directly with hospital networks and cardiology clinics, which integrate these therapeutic devices into their treatment protocols.

Revenue transactions typically involve upfront payments for the devices, along with potential ongoing service agreements for maintenance and support. Additionally, the company may engage in partnerships with healthcare providers to facilitate training and implementation of their systems, further establishing their presence in the cardiac treatment market. The pricing structure reflects the advanced technology and therapeutic benefits provided by the Coapsys® System, positioning it within the upper tier of cardiac medical devices. As of now, Myocor® Inc.

has not publicly disclosed specific upcoming products or new geographic markets targeted for expansion. The recent funding received, which amounted to USD 24. 00 mn in 2008, was utilized to support their operational growth and product development strategies, although specific details on new product launches or market entry timelines remain unspecified.